Heme oxygenase-1 regulates cell proliferation via carbon monoxide-mediated inhibition of T-type Ca\(^{2+}\) channels

Hayley Duckles · Hannah E. Boycott · Moza M. Al-Owais · Jacobo Elies · Emily Johnson · Mark L. Dallas · Karen E. Porter · Francesca Giuntini · John P. Boyle · Jason L. Scragg · Chris Peers

Abstract Induction of the antioxidant enzyme heme oxygenase-1 (HO-1) affords cellular protection and suppresses proliferation of vascular smooth muscle cells (VSMCs) associated with a variety of pathological cardiovascular conditions including myocardial infarction and vascular injury. However, the underlying mechanisms are not fully understood. Over-expression of Ca\(_{\text{3.2}}\) T-type Ca\(^{2+}\) channels in HEK293 cells raised basal [Ca\(^{2+}\)]\(_i\) and increased proliferation as compared with non-transfected cells. Proliferation and [Ca\(^{2+}\)]\(_i\) levels were reduced to levels seen in non-transfected cells either by induction of HO-1 or exposure of cells to the HO-1 product, carbon monoxide (CO) (applied as the CO releasing molecule, CORM-3). In the aortic VSMC line A7r5, proliferation was also inhibited by induction of HO-1 or by exposure of cells to CO, and patch-clamp recordings indicated that CO inhibited T-type (as well as L-type) Ca\(^{2+}\) currents in these cells. Finally, in human saphenous vein smooth muscle cells, proliferation was reduced by T-type channel inhibition or by HO-1 induction or CO exposure. The effects of T-type channel blockade and HO-1 induction were non-additive. Collectively, these data indicate that HO-1 regulates proliferation via CO-mediated inhibition of T-type Ca\(^{2+}\) channels. This signalling pathway provides a novel means by which proliferation of VSMCs (and other cells) may be regulated therapeutically.

Keywords Heme oxygenase · Carbon monoxide · Calcium channel · Proliferation · Vascular smooth muscle

Introduction

Vascular smooth muscle cells (VSMCs) control vascular tone (and hence blood flow and distribution) through regulated contraction which is highly dependent on Ca\(^{2+}\) influx, primarily via voltage-dependent L-type Ca\(^{2+}\) channels [4, 21, 33, 48, 50, 54]. VSMCs are not terminally differentiated and can undergo adaptive phenotypic changes: their ability to become non-contractile, proliferative cells is an important factor in both developmental vasculogenesis and vascular repair [35, 36, 52]. However, this switch to a proliferative state is also important in pathological situations such as atherosclerosis, restenosis, neointimal hyperplasia and hypertension [19, 36]. Given the impact of such cardiovascular diseases on global health, a greater understanding of the mechanisms underlying this phenotypic change in VSMCs has tremendous potential to reveal novel therapeutic strategies.

Although T-type Ca\(^{2+}\) channels are expressed in VSMCs, their role in vasoconstriction is unclear (see [10]). However, in proliferating VSMCs, whilst L-type Ca\(^{2+}\) channel expression decreases, T-type Ca\(^{2+}\) channel expression has long been known to increase [26, 42], and Ca\(^{2+}\) influx via T-type Ca\(^{2+}\) channels appears to be required for proliferation in vitro and neointima formation following vascular injury [26, 29, 43, 45]. The implication of a role for T-type Ca\(^{2+}\) channels has often been based on the use of mibefradil [29, 45], which is now known to exert effects on targets other than T-type Ca\(^{2+}\) channels (e.g. [15]). However, more recent molecular
approaches have confirmed this class of channel as being of primary importance in vascular proliferation [43, 47].

Heme oxygenase (HO) enzymes catalyse the degradation of heme to biliverdin, Fe$^{2+}$ and carbon monoxide (CO). Whilst HO-2 is constitutively active and widely distributed, HO-1 is induced by a variety of cellular stresses [23, 44] and regarded as protective, since heme itself is pro-oxidant, biliverdin is rapidly converted to the powerful antioxidant, bilirubin. HO-1 induction affords protection in a variety of pathological cardiovascular conditions including myocardial infarction, hypertension, atherosclerosis and vascular injury, many of which involve VSMC proliferation [8, 44]. Indeed, HO-1 is established as being anti-proliferative, and CO may account for many of the effects of HO-1 in VSMCs [12, 13, 34]: inhalation of CO can inhibit the proliferation of VSMCs in intimal hyperplasia following vessel grafting [34, 41] and CO inhalation, as well as CO-releasing molecules (CORMs), are being developed for future cardiovascular therapy [14] despite the detailed mechanisms underlying its anti-proliferative effect remaining unknown. In recent years, we and others have suggested that specific ion channels are targets of regulation by CO and that their modulation may account for some of the important actions of CO [11, 22, 46, 53].

We have most recently demonstrated that recombinant and native neuronal T-type Ca$^{2+}$ channels are inhibited by CO [5]. In the present study, we have investigated the potential role of T-type Ca$^{2+}$ channel regulation by CO on cellular proliferation.

**Methods**

**Cell culture**

A7r5 cells A7r5 cells (a smooth muscle cell line derived from rat thoracic aorta [24]) were obtained from the European Collection of Cell Cultures (ECACC, Public Health England, Porton Down, UK). They were grown in A7r5 complete media, consisting of Dulbecco's Modified Eagle Medium (DMEM) containing 10 % foetal bovine serum (FBS) (Biosera, Ringmer, UK) and 1 % glutamax (Gibco, Paisley, UK; unless otherwise stated) were transferred into a clean petri dish and a segment of vein placed in the media. This was then cut with a razorblade into fragments around 0.5 mm² in size. This tissue and media mixture was then transferred to a 25-cm² tissue culture flask and maintained in a humidified atmosphere (37 °C; 95 % air: 5 % CO₂). Cells migrated out from these tissue fragments within 7–10 days, and when 80–90 % confluent, the cells were plated for experimentation. HSVSMCs were used at passages between P1 and P6.

HEK293 cells Wild type (WT; untransfected) HEK293 cells were cultured in minimum essential medium containing Earle's salts and L-glutamine and supplemented with 10 % (v/v) foetal bovine serum (Biosera, Ringmer, UK), 1 % (v/v) non-essential amino acids, 1 % (v/v) antibiotic/antimycotic and 0.1 % (v/v) gentamicin. HEK293 cells stably expressing Ca₃.2 T-type Ca$^{2+}$ channels (a kind gift from Prof. E. Perez-Reyes; University of Virginia, VA, USA) were cultured in WT HEK293 media, additionally supplemented with 1 mg/ml G-418 to maintain selection pressure (all reagents from Gibco, Paisley, UK; unless otherwise stated). HEK293/ Ca₃.2 cells were used at passages between P1 and P8, and WT HEK293 cells were used at passages between P1 and P12; both cell types were kept in a humidified incubator at 37 °C (95 % air: 5 % CO₂) and passaged weekly.

**Proliferation assay**

Cells were plated in 24-well plates in complete media at 1 × 10⁴ cells per well. HSVSMCs were allowed to adhere overnight and subjected to serum free media (SFM) for 2.5 days. A7r5 and HEK293 cells were allowed to adhere for 6 h and then subjected to SFM overnight. On day 0 of the assay, SFM was removed and 1 ml of the relevant complete media was added to each well, in addition to the required drug or compound being investigated. To count cells, media was removed, cells were washed with 1 ml of Dulbecco’s phosphate buffered saline (PBS) and 200 μl of 0.05 % trypsin-EDTA (Gibco, Paisley, UK) was added (pre-warmed to 37 °C). Post-incubation, 800 μl of complete media was added and the cell suspension centrifuged (600g for 6 min). Following removal of 950 μl of media, 50 μl of supernatant remained with the cell pellet, which was then re-suspended with 50 μl of 0.4 % trypsin blue (Thermo Scientific, Rockford, USA) to exclude unviable cells. Media was retained from one well of each treatment, processed in the same manner as the cell samples, and any cells present were counted as an additional quantification of non-viable cells. Day 0 counts and media counts were performed using a hemocytometer. All other counts were performed using a TC10 automated cell counter (Bio-Rad, Hemel Hempstead, UK).
Western blotting

HSVSMCs, WT HEK293 and HEK293/Ca3.2 cells were grown to 80 % confluence in 6-well plates. The wells were replenished with 0.4 % serum-containing media plus the required concentration of cobalt protoporphyrin IX (CoPPIX). Post-treatment, the cells were washed with PBS and lysed via incubation for 30 min with 200 μl mammalian protein extraction reagent (M-PERTM; Thermo Scientific, Rockford, USA) containing complete protease inhibitors (Roche Diagnostics Ltd., Lewes, UK). Cell lysates were retrieved and protein levels determined using a BCA protein assay kit according to manufacturers’ instructions (Thermo Scientific, Rockford, USA). Protein (10–20 μg) containing sample buffer (250 mM Tris/HCl, pH 6.8, 4 % (w/v) SDS, 20 % (w/v) glycerol, 1 % bromophenol blue and 10 % β-mercaptoethanol) was loaded onto 12.5 %, 0.75-mm-thick polycrylamide-sodium dodecyl sulphate gels and separated for ~1 h at 35 mA before being transferred onto 0.2 μm polyvinyl difluoride membranes at 30 V overnight. Membranes were blocked using 5 % (w/v) non-fat dried milk powder in tris buffered saline (TBS)-tween (0.05 %) for 1 h, then incubated with rabbit anti-HO-1 antibody raised against amino acids 184–288 of human HO-1 (SC-10789; Santa Cruz, Dallas, USA) at 1:200 for 3 h at room temperature (21–24 °C). Mouse anti-β-actin raised against the N-terminal of β-actin (Sigma, Gillingham, UK) was used as a loading control at 1:4,000. The membranes were then washed in TBS-tween (0.05 %) and incubated with the corresponding anti-rabbit or anti-mouse peroxidase-conjugated secondary antibody (GE Healthcare, Amersham, UK) at 1:2,000 for 1 h at room temperature. Protein bands were detected using the enhanced chemi-luminescent method (GE Healthcare, Amersham, UK) on hyperfilm. Densitometric analysis was performed using Image J (NIH UK).

Electrophysiology

Ca2+ currents were recorded from A7r5 cells using the whole-cell configuration of the patch-clamp technique at room temperature (21–24 °C) as previously described [5] using an Axopatch 200A amplifier/Digidata 1300 interface controlled by Clampex 9.0 software (Molecular Devices, Sunnyvale, CA, USA). Offline analysis was performed using Clampfit 9.0. Pipettes (4–6 MΩ) were filled with (in mM) the following: CsCl 120, MgCl2 2, EGTA 10, TEA-Cl 20, HEPES 10, Na-ATP 2 and pH 7.2 (adjusted with CsOH). To optimise recording of T-type Ca2+ currents, cells were perfused with (in mM) the following: NaCl 95, CsCl 5, MgCl2 0.6, CaCl2 15, TEA-Cl 20, HEPES 5, D-glucose 10 and pH 7.4 (adjusted with NaOH). Cells were voltage-clamped at ~80 mV and either repeatedly depolarized to ~20 mV (200 ms, 0.1 Hz) or to a series of test potentials ranging from −100 to +60 mV. To record t-type Ca2+ currents, extracellular Ca2+ was replaced with 20 mM Ba2+ (pH 7.4, adjusted with NaOH) and a holding potential of ~50 mV was employed in order to inactivate T-type Ca2+ channels. Cells were repeatedly depolarized to +10 mV (200 ms, 0.1 Hz). All currents were low-pass filtered at 2 kHz and digitised at 10 kHz.

Real-time polymerase chain reaction (RT-PCR)

To determine mRNA expression levels of Ca3.2 and Ca3.1 channels, T75 flasks (70–80 % confluency) were washed with PBS and cells dissociated using 0.5 ml 0.05 % trypsin-EDTA for 3 min (37 °C; 95 % air: 5 % CO2). Enzyme activity was halted by adding 0.5-ml ice-cold PBS; the cell suspension was then centrifuged (600g for 6 min). RNA was generated from whole cell lysates using the Aurum total RNA mini kit (Bio-Rad, Hemel Hempstead, UK) following manufacturer’s instructions. A cDNA template was generated from RNA samples using the iScript cDNA synthesis kit (Bio-Rad, Hemel Hempstead, UK) following manufacturer’s instructions (reaction profile was 5 min at 25 °C, 30 min at 42 °C, 5 min at 85 °C, 5 min at 4 °C). Rat or human Taqman probes (Applied Biosystems (ABI), UK) for Ca3.1 (CACNA1G), Ca3.2 (CACNA1H) and the endogenous housekeeper hypoxanthine phosphoribosyltransferase (HPRT1) were employed for A7r5 cells and HSVSMC, respectively. In all cases, 2 μl of sample cDNA and 18 μl of RT-PCR reaction mix (10 μl Taqman universal PCR master mix, 0.5 μl Taqman probes (both from ABI) and 7.5 μl RNase/DNase-free water (Gibco, Cambridge, UK)) were added to the required wells of a 96-well PCR plate (Applied Biosystems, Cambridge, UK). RT-PCR was carried out using an ABI 7500 real-time PCR system (reaction profile was 2 min at 50 °C, 10 min at 95 °C, 15 s at 95 °C for 60 cycles, 1 min at 60 °C). Data were analysed using the 7500 software (ABI) and relative gene expression calculated using the 2−ΔΔCT method with HPRT1 as the endogenous control.

Ca2+ microfluorimetry

WT HEK293 or HEK293/Ca3.2 cells were plated at the required cell density on circular glass coverslips (10 mm, thickness 0) and allowed to adhere overnight. Cells were washed and incubated with 4 μM Fura 2-AM (Invitrogen, Cambridge, UK) diluted in HEPES-buffered saline for 40 min at room temperature (21–24 °C). Composition of HEPES-buffered saline was (in mM): NaCl 135, KCl 5, MgSO4 1.2, CaCl2 2.5, HEPES 5, glucose 10, osmolarity adjusted to 300 mOsm with sucrose, and pH adjusted to 7.4. The Fura 2-containing saline was removed after 40 min and replaced with HEPES-buffered saline for 15 min to allow deesterification. Coverslip fragments were loaded into a
perfusion chamber on an inverted epifluorescence microscope, and the cells were superfused via gravity at 2–3 ml/min. 

\[ [\text{Ca}^{2+}] \] was indicated by fluorescence emission measured at 510 nm as a result of alternating excitation at 340 and 380 nm using a Cairn Research ME-SE Photometry system (Cairn Research, Cambridge, UK). Baseline readings were obtained on exposure to HEPES-buffered saline, and \( \text{Ca}^{2+} \) homeostasis was monitored in response to the addition of a drug, or in response to \( \text{Ca}^{2+} \)-free HEPES-buffered saline (composition as above, but with \( \text{CaCl}_2 \) replaced by 1 mM EGTA).

Statistical comparisons were made using, as appropriate, paired or unpaired student’s t tests, one-way ANOVA with a multiple comparison test or repeated measures one-way ANOVA with a multiple comparison test.

Results

CO regulation of T-type \( \text{Ca}^{2+} \) channels regulates proliferation in A7r5 cells

The known role of T-type \( \text{Ca}^{2+} \) channels in proliferation (see “Introduction”), together with our recent study indicating that CO can directly modulate T-type \( \text{Ca}^{2+} \) channels [5], indicates that HO-1-derived CO can limit proliferation via inhibition of T-type \( \text{Ca}^{2+} \) channels. To investigate this, we employed A7r5 cells, which are derived from rat aortic smooth muscle [24] and express T-type \( \text{Ca}^{2+} \) channels as well as L-type \( \text{Ca}^{2+} \) channels [6, 30, 39]. Mibefradil caused a concentration-dependent decrease in proliferation, as determined after 3 days, without loss of cell viability (Fig. 1a). By contrast, nifedipine did not significantly affect proliferation over the same time period at concentrations up to 4 \( \mu \text{M} \) (Fig. 1b). A previous electrophysiological study indicated that at 1 \( \mu \text{M} \) mibefradil was selective for T-type over L-type \( \text{Ca}^{2+} \) channels in A7r5 cells [6], but did not explore higher concentrations. Therefore, to probe the role of T-type \( \text{Ca}^{2+} \) channels in proliferation further, we also found that an alternative and more selective T-type \( \text{Ca}^{2+} \) channel blocker, NNC-55-0396 [20], significantly reduced proliferation at 3 \( \mu \text{M} \) (Fig. 1c), but was toxic to cells at higher concentrations (not shown). Finally, we investigated the effects of Ni\( ^{2+} \), a known T-type \( \text{Ca}^{2+} \) channel inhibitor. Importantly, these studies were performed in the presence of 2 \( \mu \text{M} \) nifedipine in order to prevent any potential influence of L-type \( \text{Ca}^{2+} \) channel blockade by Ni\( ^{2+} \) on proliferative responses. Ni\( ^{2+} \) caused a concentration-dependent inhibition of proliferation, as shown in Fig. 1d. The data presented in Fig. 1 strongly suggest that \( \text{Ca}^{2+} \) influx via T-type, but not L-type \( \text{Ca}^{2+} \) channels, contributes to the proliferation of A7r5 cells.

Exposure of A7r5 cells to CoPPIX caused a concentration-dependent increase in the expression of HO-1, as detected by Western blotting (Fig. 2a). This procedure for induction of HO-1 caused a significant reduction of proliferation in A7r5 cells (Fig. 2b). Furthermore, proliferation of A7r5 cells was strikingly reduced by exposure of cells to CORM-3 (Fig. 2c). Collectively, the data presented in Figs. 1 and 2 suggest that proliferation in A7r5 cells is dependent on T-type \( \text{Ca}^{2+} \) channel activity and can be inhibited by induction of HO-1 or exposure to CO. To investigate whether CO acted via inhibition of native T-type \( \text{Ca}^{2+} \) channels in these cells, we examined their activity using whole-cell patch-clamp recordings. T-type \( \text{Ca}^{2+} \) channel currents, recorded using a holding potential of \( -80 \text{ mV} \) and \( \text{Ca}^{2+} \) as the charge carrier, were inhibited by exposure of cells to CORM-2 but not to iCORM (Fig. 3a, c). Where tested (e.g. Fig. 3a), these currents were also inhibited by 3 \( \mu \text{M} \) NNC 55-0396 (93.2±5.9 % inhibition, \( n=5 \)). To study L-type \( \text{Ca}^{2+} \) currents, we used a holding potential of \( -50 \text{ mV} \) (in order to inactivate T-type \( \text{Ca}^{2+} \) channels) and replaced \( \text{Ca}^{2+} \) with \( \text{Ba}^{2+} \) to promote influx via L-type rather than T-type \( \text{Ca}^{2+} \) channels. Under these conditions, currents displaying little or no inactivation were also inhibited by CORM-2 but not iCORM (Fig. 3b, c) and, where tested (e.g. Fig. 3b), were inhibited by 2 \( \mu \text{M} \) nifedipine (88.5±6.2 % inhibition, \( n=5 \)). Thus, CO can inhibit both T-type and L-type \( \text{Ca}^{2+} \) channels natively expressed in A7r5 cells.

HO-1 and CO inhibit proliferation in HSVSMCs

To examine whether the HO-1/CO pathway was able to modify proliferation in human VSMCs, we studied cells cultured from human saphenous vein. Figure 4a shows that HO-1 could be induced in these cells in a concentration-dependent manner and that induction was clearly detectable at 2 and 4 days (the duration of associated proliferation studies). Induction of HO-1 also led to a concentration-dependent inhibition of proliferation over this same time period, without loss of cell viability (Fig. 4b). To investigate whether the reduced proliferation observed following HO-1 induction was attributable to the production of CO, we exposed cells to CORM-3 and found that this agent caused a concentration-dependent inhibition of proliferation, again without any loss of cell viability (Fig. 4c).

Figure 5a shows a proliferation time-course experiment from HSVSMCs, and again demonstrates the inhibitory effect of HO-1 induction, using 3 \( \mu \text{M} \) CoPPIX. A qualitatively and quantitatively similar effect was found when cells were exposed to the known T-type \( \text{Ca}^{2+} \) channel blocker, mibefradil (3 \( \mu \text{M} \); Fig. 5b), which was without effect on cell viability (data not shown). Finally, proliferation was again reduced by a similar amount in cells in which HO-1 had been induced, and during an additional exposure to mibefradil (Fig. 5c), indicating that HO-1 and mibefradil are non-additive, likely because they act via the same target, the T-type \( \text{Ca}^{2+} \) channel.
Figure 6 shows the expression levels, relative to the endogenous housekeeper HPRT1, of mRNA for the T-type Ca\(^{2+}\) channel isoforms, Cav3.1 and Cav3.2, as determined by RT-PCR. In both the A7r5 cells and HSVSMCs, the Cav3.1 isoform is expressed at significantly higher levels than the Cav3.2 isoform, but both isoforms were detected.

CO inhibits augmented proliferation in Cav3.2-expressing HEK293 cells

In order to better understand the cellular mechanisms underlying CO modulation of T-type Ca\(^{2+}\) channels and how this impacts on proliferation, we employed a recombinant expression system. Preliminary studies in HEK293 cells stably expressing Cav3.1 indicated that these cells readily formed clumps and became detached in culture, making assessment of their effects on proliferation difficult. We therefore focussed on cells over-expressing Cav3.2, which are also expressed in VSMCs (see [49] as well as Fig. 6), and are equally potently modulated by CO [5]. In agreement with a previous report [17], we found that over-expression of Cav3.2 in HEK293 cells increased their proliferation when compared with WT cells over a 3-day period (Fig. 7a, b). Exposure of WT cells to the CO-releasing molecule CORM-3 (30 \(\mu\)M) or the inactive, control compound iCORM (30 \(\mu\)M) was without significant effect on proliferation (Fig. 7a). By contrast, exposure of Cav3.2-expressing cells to 30 \(\mu\)M CORM-3 (but not iCORM) significantly reduced proliferation (Fig. 7b).

Proliferation monitored after 3 days also revealed that mibefradil (3 \(\mu\)M) was without significant effect in WT cells (Fig. 7c), but reduced proliferation in Cav3.2-expressing cells to levels observed in WT cells, and CORM-3 was without further effect in the presence of mibefradil (Fig. 7d).

Cav3.2 over-expression increases basal \([\text{Ca}^{2+}]_\text{i}\)

Tonic Ca\(^{2+}\) entry via the window current generated in cells expressing T-type Ca\(^{2+}\) channels is believed to regulate cell proliferation (see “Introduction”). We employed fluorimetric recordings from Fura-2 loaded HEK293 cells to both monitor Ca\(^{2+}\) levels and determine how they were influenced by T-type Ca\(^{2+}\) channel expression. Basal [Ca\(^{2+}\)], in HEK293 cells expressing Cav3.2 was significantly higher than levels observed in WT cells, and removal of extracellular Ca\(^{2+}\) (replaced with 1 mM EGTA) caused a fall of [Ca\(^{2+}\)], which was far larger than that seen in WT cells (although the same manoeuvre also caused a significant decrease of [Ca\(^{2+}\)], in these cells; Fig. 8a), in agreement with an earlier report [9]. To determine whether the elevated [Ca\(^{2+}\)], was attributable to Ca\(^{2+}\) influx via the...
T-type Ca\(^{2+}\) channel window current, we investigated the effects of the T-type Ca\(^{2+}\) channel blockers Ni\(^{2+}\) (30 μM; Fig. 8b), mibefradil (3 μM; Fig. 8c) and NNC55-0396 (3 μM; Fig. 8d). All blockers caused significant reductions in [Ca\(^{2+}\)], and in the case of Ni\(^{2+}\), this effect was at least partly reversible. None of the inhibitors tested significantly altered [Ca\(^{2+}\)] in WT cells (Fig. 8b–d).

HO-1 and CO regulate [Ca\(^{2+}\)], in Ca,3,2-expressing cells

We next investigated the effects of HO-1 induction on [Ca\(^{2+}\)] in HEK293 cells. As illustrated in Fig. 9a, HO-1 induction with 10 μM cobalt protoporphyrin IX (CoPPIX) for 48 h caused a significant reduction in basal [Ca\(^{2+}\)] in cells expressing Ca,3,2, although removal of extracellular Ca\(^{2+}\) reduced
[Ca^{2+}]	ext{ further. By contrast, HO-1 induction with 3 μM CoPPIX in WT HEK293 cells was without significant effect (Fig. 9a). This slightly lower concentration of CoPPIX was selected for WT HEK293 cells, since it was found to be the optimal concentration for HO-1 induction, as determined by Western blotting, whereas in Cav3.2-expressing cells, maximal induction was achieved with 10 μM CoPPIX (Fig. 9b). To determine whether CO mediated the effects of HO-1 induction on resting [Ca^{2+}], we applied CORM-3 (3 μM), which caused a striking and largely irreversible reduction of [Ca^{2+}] in Cav3.2-expressing HEK293 cells, but not in WT cells (Fig. 9c). By contrast, iCORM was without significant effect in either cell type (Fig. 9c).

Collectively, these fluorimetric studies indicate that over-expression of Cav3.2 generates a detectable tonic Ca^{2+} influx in HEK293 cells which can be suppressed either by CO or following induction of HO-1.

**Discussion**

Although Ca^{2+} influx via L-type Ca^{2+} channels is important for VSMC contraction, a reduction in their expression is associated with the proliferative phenotypic change [16, 19], as observed in pathological models involving VSMC proliferation [40]. However, Ca^{2+} influx is still needed for the progression of proliferation since it regulates the activity of numerous transcription factors, e.g. NFAT (nuclear factor of activated T-cells; [2]). Some studies suggest TRP (transient receptor potential) channels, particularly TRPC channels, contribute to Ca^{2+} influx during VSMC proliferation [19, 27]. Further evidence indicates STIM1/Orai-mediated Ca^{2+} entry is also involved in VSMC proliferation, migration and neointima formation in vivo [3, 56]. However, there is also compelling evidence for the involvement of voltage-gated T-type Ca^{2+} channels in VSMC proliferation. Indeed, in proliferating

---

**Fig. 4** HO-1 and CO inhibit proliferation in human saphenous vein SMCs. **a** Bar graphs showing the relative HO-1 protein expression in HSVSMCs following 48 h (left) and 96 h (right) exposure to CoPPIX at the concentrations indicated; densitometric analyses were normalised to β-actin (n=3 in each case). CoPPIX treatment was added at 0 and 48 h. Data are represented as mean±s.e.m., and data were analysed by one-way ANOVA with Dunnett’s multiple comparison test; statistical significance *p<0.05 vs control levels. Representative Western blots of HO-1 and the corresponding β-actin loading control at 48 and 96 h are shown below. 

**b** Bar graph showing the proliferative response of HSVSMC (plotted against corresponding left y-axis) to increasing concentrations of CoPPIX. The open circles show the corresponding unviable cell count (plotted against corresponding right y-axis). Statistical significance **p<0.01, ***p<0.001 vs day 3 control (no CoPPIX). Data are represented as mean±s.e.m. (n=4). Data analysed via one-way ANOVA (a), or ratio repeated measures one-way ANOVA followed by Dunnett’s multiple comparison test (b and c).
VSMCs, as L-type Ca\(^{2+}\) channel expression decreases, there is a concomitant increase in T-type Ca\(^{2+}\) channel expression [26, 42]. Evidence suggests Ca\(^{2+}\) influx via T-type Ca\(^{2+}\) channels is required for VSMC proliferation in vitro and in neointima formation observed following vascular injury [26, 29, 43, 45]. Although the implication of a role for T-type Ca\(^{2+}\) channels has often (but not always) been based on the use of mibefradil (which was originally proposed as a selective T-type Ca\(^{2+}\) channel blocker but has since been shown to exert other effects, such as inhibition of store-operated Ca\(^{2+}\) entry [15]),

![Fig. 5 Mibefradil and HO-1 induction are non-additive in suppressing human saphenous vein SMC proliferation. a–c Line graphs showing proliferation of HSVSMCs monitored over a 4-day period, in the absence of drug treatment (solid circles), or during HO-1 induction with 3 μM CoPPIX (open symbols, a), or in the presence of 3 μM mibefradil (open circles, b), or during simultaneous application of 3 μM mibefradil and 3 μM CoPPIX (open circles, c). Each point represents mean±s.e.m. (n=5). Statistical significance *p<0.05, **p<0.01. Data analysed via repeated measures one-way ANOVA followed by Sidak’s multiple comparison test between control and treated groups for each timepoint.

![Fig. 6 Expression levels for Ca,3.1 and Ca,3.2 mRNA determined in A7r5 cells and HSVSMCs, as indicated. Channel expression is plotted as mean±s.e.m. percentage of expression of the housekeeping gene, hypoxanthine phosphoribosyltransferase (HPRT1), taken from 7 A7r5 samples and 6 HSVSMC samples. Statistical significance *p<0.05, data analysed via unpaired t test.

![Fig. 7 CO inhibits the augmented proliferation observed in Cav3.2-expressing HEK293 cells. a and b Plots of mean (± s.e.m., n=3) proliferation monitored in untransfected (wild type; WT) and Cav3.2-expressing HEK293 cells, as indicated. Cells were cultured in the absence of drugs (solid circles), or in the presence of either CORM-3 (30 μM; open circles) or iCORM (30 μM solid triangles). c and d Bar graphs illustrating the effects of mibefradil and CORM-3 (applied separately or together, as indicated) on proliferation measured on day 3 in WT (c) and Cav3.2-expressing HEK293 cells (d). Each bar represents mean (± s.e.m.) proliferation determined from 9 repeats. Statistical significance: **p<0.01 as compared with controls. Data analysed via ratio repeated measures one-way ANOVA followed by Dunnett’s multiple comparison test.]
mibefradil clearly blocks T-type Ca\textsuperscript{2+} channels, inhibits proliferation associated with vascular injury-mediated neointima formation and NFAT-mediated transcriptional activity [29, 45]. Furthermore, in the pulmonary vasculature, evidence for T-type Ca\textsuperscript{2+} channels regulating proliferation comes also from siRNA-targeted T-type (Cav3.1) Ca\textsuperscript{2+} channel knock-down [43]. Most convincingly, murine knockout models have recently shown beyond doubt that Cav3.1 is required for VSMC proliferation following systemic vascular injury [47].

In VSMCs expressing native T-type Ca\textsuperscript{2+} channels (A7r5 cells and HSVSMCs), data presented are also consistent with these channels exerting an important influence on proliferation. Consistent with previous work [49], we detected expression of both Cav3.1 and Cav3.2 in A7r5 cells, and also detected mRNA for both channel types in HSVSMCs (Fig. 6), and mibefradil reduced proliferation in both cell types (Figs. 1 and 5). In A7r5 cells, despite the presence of nifedipine-sensitive L-type Ca\textsuperscript{2+} channels (Fig. 3), nifedipine was without effect on proliferation (Fig. 1), which discounts the possibility that mibefradil (or indeed NNC 55-0396) reduced proliferation via a non-selective blockade of L-type Ca\textsuperscript{2+} channels. Ni\textsuperscript{2+} (studied in the presence of nifedipine) was effective at reducing proliferation only at higher (>100 \( \mu \)M) concentrations. This suggests that influx of Ca\textsuperscript{2+} into A7r5 cells via T-type Ca\textsuperscript{2+} channels predominantly involves Cav3.1 rather than Cav3.2 channels, since Cav3.2 channels would

---

**Fig. 8** T-type Ca\textsuperscript{2+} channels influence basal [Ca\textsuperscript{2+}] in Cav3.2-expressing HEK293 cells. **a** Upper traces show examples of basal [Ca\textsuperscript{2+}], recorded in Cav3.2-expressing and untransfected (wild type; WT) HEK293 cells, as annotated. For the periods indicated by the horizontal bars, extracellular Ca\textsuperscript{2+} was replaced with 1 mM EGTA. Below, bar graph illustrating the mean basal [Ca\textsuperscript{2+}], levels (with s.e.m. bars) recorded in Cav3.2-expressing cells (open bars, n=6) and WT cells (shaded bars, n=6) in the presence and absence of extracellular Ca\textsuperscript{2+}, as indicated. **b** Upper traces show examples of basal [Ca\textsuperscript{2+}], recorded in Cav3.2-expressing and WT HEK293 cells and the effects of Ni\textsuperscript{2+} (30 \( \mu \)M), applied for the periods indicated by the horizontal bars. Below, bar graph illustrating the mean (± s.e.m.) basal [Ca\textsuperscript{2+}], levels recorded in Cav3.2-expressing cells (open bars, n=6) and WT cells (shaded bars, n=6) before (con.), during (Ni\textsuperscript{2+}) and after (wash) exposure to Ni\textsuperscript{2+}, as indicated. **c** and **d** as **b**, except that cells were exposed to 3 \( \mu \)M mibefradil (mib; c) or 3 \( \mu \)M NNC55-0396 (NNC; d) for the periods indicated by the horizontal bars. Corresponding bar graphs illustrate mean (± s.e.m.) basal [Ca\textsuperscript{2+}], levels recorded in Cav3.2-expressing cells and WT cells before (con.), during (mib or NNC) and after (wash) exposure to mibefradil (c n=7) or NNC (d n=8), as indicated. Statistical significance *P<0.05; **P<0.01, ***P<0.001 as compared with appropriate controls. Data analysed via paired or unpaired t test as appropriate.
be expected to be already fully inhibited at these higher Ni\textsuperscript{2+} concentrations [28].

The major finding of the present study is that HO-1 induction leads to reduced proliferation in VSMCs (both A7r5 cells, Fig. 1, and HSVSMCs, Figs. 4 and 5) and that this occurs via CO formation which in turn inhibits T-type Ca\textsuperscript{2+} channels. Thus, reduced proliferation arising from HO-1 induction could be mimicked by application of the CO-donor CORM-3 in both cell types (Figs. 2 and 4), and in A7r5 cells, we were able to demonstrate directly that T-type Ca\textsuperscript{2+} channels were inhibited by CORM-2 (Fig. 3). It should be noted that we could not use CORM-2 for proliferation studies, since cells did not tolerate long-term exposure to its solvent, DMSO (data not shown). CO also inhibited L-type Ca\textsuperscript{2+} channels (as we have previously shown in cardiac myocytes [46]), but this appears to be without influence on proliferation, since proliferation was insensitive to nifedipine (Fig. 1b). The reason why L-type Ca\textsuperscript{2+} channels do not influence proliferation in these
Fig. 9  HO-1 and CO modulate basal [Ca\(^{2+}\)] in Ca\(_{3.2}\)-expressing HEK293 cells. a Upper traces show examples of basal [Ca\(^{2+}\)], recorded in Ca\(_{3.2}\)-expressing cells (left traces and bar graph) and WT cells (right traces and bar graph). Cells received either no pre-treatment, or were exposed to 10 μM CoPPIX (Ca-3.2) or 3 μM CoPPIX (WT) for 48 h to induce HO-1 expression (+CoPPIX). b Western blots showing the concentration-dependent induction of HO-1 expression by CoPPIX. Corresponding β-actin blots are shown below, and data were obtained in Ca\(_{3.2}\)-expressing (left) and WT (right) HEK293 cells. c Upper traces show examples of basal [Ca\(^{2+}\)], recorded in Ca\(_{3.2}\)-expressing and WT HEK293 cells, as indicated, and the effects of CORM-3 (3 μM; left traces) and iCORM (3 μM; right traces) applied for the periods indicated by the horizontal bars. Shaded bars; statistical significance **P<0.01, ***P<0.001 as compared with appropriate controls. Data analysed via paired or unpaired t test as appropriate.

The presence of a window current generated by expressed Ca\(_{3.2}\) channels would also require that native currents set the resting membrane potential appropriately. The nature of such currents has not to date been explored in depth.

Numerous studies have indicated that HO-1 induction affords protection in a variety of pathological systemic cardiovascular conditions, many of which involve VSMC proliferation [8, 44]. Indeed, HO-1 is established as being anti-proliferative, and its induction is observed in these proliferative vascular diseases. For example, proliferation associated with hypertension is suppressed by HO-1 induction [7], and many studies have indicated that HO-1 protects against inflammation and oxidative stress associated with atherosclerosis [1]. Furthermore, whilst bilirubin is a powerful antioxidant in its own right, evidence points towards CO as accounting for many of the effects of HO-1 in VSMCs [12, 13, 34]. For example, inhalation of CO inhibits VSMC proliferation in intimal hyperplasia following vessel grafting [34, 41] and CO inhalation, as well as CO-releasing molecules (CORMs), is being developed for future cardiovascular therapy [14, 32].

HO-1 is also influential in the pulmonary vasculature: hypoxic induction of pulmonary hypertension (and hence right ventricular dilation) was far worse in HO-1\(^{-/-}\) mice [55], and targeted pulmonary over-expression of HO-1 prevents inflammation and pulmonary vessel wall hypertrophy (including VSMC proliferation) in response to hypoxia [31]. Clearly, HO-1 is beneficial in providing protection against pulmonary remodelling, and speculation that CO mediates these effects of HO-1 has been made in earlier publications [25]. More recent studies have provided direct evidence that CO inhalation in HO-1\(^{-/-}\) mice prevented hypoxic pulmonary remodelling and inhibited hypoxic VSMC proliferation in vitro, whereas biliverdin was ineffective [51].

Despite these numerous accounts of the beneficial effects of CO derived from HO-1 induction in both systemic and pulmonary vascular diseases, no mechanism has been proposed to account for such effects to date. The data presented here provide compelling evidence that CO may provide protection against proliferative vascular diseases at least in part via inhibition of T-type Ca\(^{2+}\) channels. Since CO can regulate all three isoforms of T-type Ca\(^{2+}\) channels (Ca\(_{3.1}\), 3.2 and 3.3 [5]), this regulation can occur regardless of which isoform is expressed. The present data therefore provide mechanistic insight into the beneficial cardiovascular effects of HO-1 and CO and also point to a novel signalling pathway which can be targeted in future treatment strategies for vascular diseases.

Acknowledgments This work was supported by the British Heart Foundation.
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Araujo JA, Zhang M, Yin F (2012) Heme oxygenase-1, oxidation, inflammation, and atherosclerosis. Front Pharmacol 3:119
2. Barbado M, Fablet K, Ronjat M, De WM (2009) Gene regulation by voltage-dependent calcium channels. Biochim Biophys Acta 1793: 1096–1104
3. Beech DJ (2012) Orai calcium channels in the vasculature. Pflugers Arch 463:635–647
4. Bolton TB, MacKenzie I, Aaronson PI (1988) Voltage-dependent calcium channels in smooth muscle cells. J Cardiovasc Pharmacol 12(Suppl 6):S3–S7
5. Boycott HE, Dallas ML, Elies J, Pettinger L, Boyle JP, McLatchie L, Harper J, Brooks G, Heady T, Macdonald TL (2004) Haller H (1998) L-type calcium channel expression depends on the
6. Brueggemann LI, Martin BL, Barakat J, Byron KL, Cribbs LL (2006) T-type Ca2+ channel blockers suppress the growth of human cancer cells. Bioorg Med Chem Lett 18:3899–3901
7. Cao J, Inoue K, Li X, Drummond G, Abraham NG (2009) Physiological significance of heme oxygenase in hypertension. Int J Biochem Cell Biol 41:1025–1033
8. Chang T, Wu L, Wang R (2008) Inhibition of vascular smooth muscle cell proliferation by chronic heme treatment. Am J Physiol Heart Circ Physiol 288:H923–H935
9. Chemin J, Monteil A, Briquaire C, Richard S, Perez-Reyes E, Mornet D, Richard S (2001) Transient down-regulation of L-type calcium channels and AVP-stimulated calcium spiking. Am J Physiol Heart Circ Physiol 288:H923–H935
10. Cribbs LL (2006) T-type Ca2+ channels in non-excitable smooth muscle: calcium signaling and phenotypic switching during vascular disease. Pflugers Arch 456:769–785
11. Dallas ML, Scragg JL, Peers C (2008) Modulation of hTREK-1 by multiple functions. Cell Calcium 40:221
12. Durante W (2003) Heme oxygenase-1 in growth control and its non-excitable smooth muscle: calcium signaling and phenotypic switching during vascular disease. Pflugers Arch 456:769–785
13. Durant W (2003) Heme oxygenase-1 in growth control and its non-excitable smooth muscle: calcium signaling and phenotypic switching during vascular disease. Pflugers Arch 456:769–785
14. Foresti R, Bani-Hani MG, Motterlini R (2008) Use of carbon monoxide as a therapeutic agent: promises and challenges. Intensive Care Med 45(3):563–685
15. Gamper N, Peers C (2013) Carbon monoxide inhibition of Cav3.2 T-type Ca2+ channels reveals tonic modulation by thioredoxin. FASEB J 27:3395–3407
16. Gray LS, Perez-Reyes E, Gomora JC, Haverstick DM, Shattock M, McLatchie L, Harper J, Brooks G, Heady T, Macdonald TL (2004) The role of voltage gated T-type Ca2+ channel isoforms in mediating “capacitative” Ca2+ entry in cancer cells. Cell Calcium 36:489–497
17. Heo JH, Seo HN, Choe YJ, Kim S, Oh CR, Kim YD, Rhim H, Choo DJ, Kim J, Lee JY (2008) T-type Ca2+ channel blockers suppress the growth of human cancer cells. Bioorg Med Chem Lett 18:3899–3901
18. Huang L, Keyser BM, Tagmose TM, Hansen JB, Taylor JT, Zhuang H, Zhang M, Ragsdale DS, Li M (2004) NCC 55-0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl)propyl]-N methylamino)ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels. J Pharmacol Exp Ther 309:193–199
19. Jackson WF (2000) Ion channels and vascular tone. Hypertension 35:173–178
20. Jaggar JH, Li A, Parfenova H, Liu J, Umstot ES, Dopico AM, Leffler CW (2005) Heme is a carbon monoxide receptor for low-conductance Ca2+-activated K+ channels. Circ Res 97:805–812
21. Kim HP, Ryter SW, Choi AM (2006) CO as a cellular signaling molecule. Annu Rev Pharmacol Toxicol 46:411–449
22. Kimes BW, Brandt BL (1976) Characterization of two putative smooth muscle cell lines from rat thoracic aorta. Exp Cell Res 98:349–366
23. Kowrembans S (2002) Hypoxia and carbon monoxide in the vasculature. Antioxid Redox Signal 4:291–299
24. Koga T, Kobayashi S, Hiraoka Y, Kanaide H, Takeshita A (1996) Cell cycle-dependent expression of L- and T-type Ca2+ currents in rat aortic smooth muscle cells in primary culture. Circ Res 79:14–19
25. Kumar B, Dreja K, Shah SS et al (2006) Upregulated TRPC1 channel in vascular injury in vivo and its role in human neointimal hyperplasia. Circ Res 98:557–563
26. Lee JH, Gongora JC, Cribs LL, Perez-Reyes E (1999) Nickel block of three cloned T-type calcium channels: low concentrations selectively block alpha1H. Biophys J 77:3034–3042
27. Lipskaia L, Hulot JS, Lompre AM (2009) Role of sarco/endoplasmic reticulum calcium content and calcium ATPase activity in the control of cell growth and proliferation. Pflugers Arch 457:673–685
28. Marks TN, Dubyk GR, Jones SW (1990) Calcium currents in the A7r5 smooth muscle-derived cell line. Pflugers Arch 417:433–439
29. Minamino T, Christou H, Hsieh CM, Liu Y, Dhwani V, Abraham NG, Perrella MA, Mitsialis SA, Kourembans S (2001) Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc Natl Acad Sci U S A 98:8798–8803
30. Motterlini R, Otterbein LE (2010) The therapeutic potential of carbon monoxide. Nat Rev Drug Discov 9:728–743
31. Nelson MT, Patlak JB, Worley JF, Standen NB (1990) Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone. Am J Physiol 259:C3–C18
32. Otterbein LE, Zuckerbraun BS, Haga M et al (2003) Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. Nat Med 9:183–190
33. Owens GK (1995) Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 75:487–517
34. Owens GK, Kumar MS, Wamhoff BR (2004) Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 84:767–801
35. Panner A, Wurster RD (2006) T-type calcium channels and tumor proliferation. Cell Calcium 40:253–259
36. Perez-Reyes E (2003) Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev 83:117–161
37. Pluteanu F, Cribs LL (2011) Regulation and function of Cav3.1 T-type calcium channels in IGF-1-stimulated pulmonary artery smooth muscle cells. Am J Physiol Cell Physiol 300:C517–C525
38. Quignard JF, Harricane MC, Menard C, Lory P, Nargeot J, Capron L, Mornet D, Richard S (2001) Transient down-regulation of T-type calcium channels in smooth muscle cells. J Cardiovasc Pharmacol 36(3):188–198
39. Ramlawi B, Scott JR, Feng J et al (2007) Inhaled carbon monoxide prevents graft-induced intimal hyperplasia in swine. J Surg Res 138:121–127
42. Richard S, Neveu D, Carnac G, Bodin P, Travo P, Nargeot J (1992) Differential expression of voltage-gated Ca(2+)-currents in cultivated aortic myocytes. Biochim Biophys Acta 1160:95–104
43. Rodman DM, Reese K, Harral J et al (2005) Low-voltage-activated (T-type) calcium channels control proliferation of human pulmonary artery myocytes. Circ Res 96:864–872
44. Ryter SW, Alam J, Choi AM (2006) Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev 86:583–650
45. Schmitt R, Clozel JP, Iberg N, Buhler FR (1995) Mibebradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel. Arterioscler Thromb Vasc Biol 15:1161–1165
46. Scruggs JL, Dallas ML, Wilkinson JA, Varadi G, Peers C (2008) Carbon monoxide inhibits L-type Ca2+ channels via redox modulation of key cysteine residues by mitochondrial reactive oxygen species. J Biol Chem 283:24412–24419
47. Tzeng BH, Chen YH, Huang CH, Lin SS, Lee KR, Chen CC (2012) The Cav3.1 T-type calcium channel is required for neointimal formation in response to vascular injury in mice. Cardiovasc Res 96:533–542
48. Van BC, Cauvin C, Johns A, Leijten P, Yamamoto H (1986) Ca2+ regulation of vascular smooth muscle. Fed Proc 45:2746–2751
49. VanBavel E, Sorop O, Andreassen D, Pfaffendorf M, Jensen BL (2002) Role of T-type calcium channels in myogenic tone of skeletal muscle resistance arteries. Am J Physiol Heart Circ Physiol 283: H2239–H2243
50. Vanhoutte PM (1985) Calcium-entry blockers, vascular smooth muscle and systemic hypertension. Am J Cardiol 55:17B–23B
51. Vitali SH, Mitsialis SA, Liang OD, Liu X, Fernandez-Gonzalez A, Christou H, Wu X, McGowan FX, Kourembanas S (2009) Divergent cardiopulmonary actions of heme oxygenase enzymatic products in chronic hypoxia. PLoS One 4:e5978
52. Wamhoff BR, Bowles DK, Owens GK (2006) Excitation-transcription coupling in arterial smooth muscle. Circ Res 98:868–878
53. Williams SE, Wootton P, Mason HS, Bould J, Iles DE, Riccardi D, Peers C, Kemp PJ (2004) Hemoxygenase-2 is an oxygen sensor for a calcium-sensitive potassium channel. Science 306:2093–2097
54. Xiong Z, Sperelakis N (1995) Regulation of L-type calcium channels of vascular smooth muscle cells. J Mol Cell Cardiol 27:75–91
55. Yet SF, Perrella MA, Layne MD, Hsieh CM, Maemura K, Kobzik L, Wiesel P, Christou H, Kourembanas S, Lee ME (1999) Hypoxia induces severe right ventricular dilatation and infarction in heme oxygenase-1 null mice. J Clin Invest 103:R23–R29
56. Zhang W, Halligan KE, Zhang X et al (2011) Orai1-mediated I(CRAC) is essential for neointima formation after vascular injury. Circ Res 109:534–542